The majority of approaches for defined antigens target TAAs (40.8% of known antigen listings), the most common including WT1 (leukemia) and HER2 (breast cancer), along with survivin, hTERT, and NY‐ESO‐1 (various solid tumors) (Figure 7c, Table S7). This evidence concerns the gene ERBB2 and breast carcinoma.